Maxwell Skor
Stock Analyst at Morgan Stanley
(2.53)
# 2,245
Out of 5,135 analysts
7
Total ratings
50%
Success rate
22.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Initiates: Overweight | $115 | $55.48 | +107.28% | 1 | Jan 9, 2026 | |
| INSM Insmed | Maintains: Equal-Weight | $126 → $144 | $151.11 | -4.71% | 1 | Aug 21, 2025 | |
| ASND Ascendis Pharma | Assumes: Overweight | $250 | $226.83 | +10.21% | 1 | Jul 3, 2025 | |
| SANA Sana Biotechnology | Assumes: Overweight | $12 | $3.93 | +205.34% | 1 | Jul 3, 2025 | |
| TCRX TScan Therapeutics | Assumes: Overweight | $10 | $1.02 | +880.39% | 1 | Mar 14, 2025 | |
| IVVD Invivyd | Maintains: Overweight | $9.5 → $3.55 | $1.65 | +115.15% | 2 | Nov 20, 2024 |
Monopar Therapeutics
Jan 9, 2026
Initiates: Overweight
Price Target: $115
Current: $55.48
Upside: +107.28%
Insmed
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $126 → $144
Current: $151.11
Upside: -4.71%
Ascendis Pharma
Jul 3, 2025
Assumes: Overweight
Price Target: $250
Current: $226.83
Upside: +10.21%
Sana Biotechnology
Jul 3, 2025
Assumes: Overweight
Price Target: $12
Current: $3.93
Upside: +205.34%
TScan Therapeutics
Mar 14, 2025
Assumes: Overweight
Price Target: $10
Current: $1.02
Upside: +880.39%
Invivyd
Nov 20, 2024
Maintains: Overweight
Price Target: $9.5 → $3.55
Current: $1.65
Upside: +115.15%